Everett Harris & Co. CA raised its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 5.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 236,761 shares of the biopharmaceutical company's stock after purchasing an additional 12,508 shares during the period. Everett Harris & Co. CA's holdings in Pfizer were worth $6,000,000 as of its most recent SEC filing.
Other institutional investors have also modified their holdings of the company. Clarity Asset Management Inc. acquired a new stake in shares of Pfizer during the fourth quarter worth about $27,000. Gould Capital LLC increased its position in Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares during the period. North Capital Inc. purchased a new stake in Pfizer in the first quarter valued at approximately $28,000. Bayforest Capital Ltd purchased a new stake in Pfizer in the first quarter valued at approximately $28,000. Finally, Bernard Wealth Management Corp. acquired a new stake in shares of Pfizer in the fourth quarter valued at approximately $30,000. Hedge funds and other institutional investors own 68.36% of the company's stock.
Analysts Set New Price Targets
A number of brokerages have recently commented on PFE. HSBC cut their target price on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Cantor Fitzgerald started coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective on the stock. BMO Capital Markets reduced their target price on shares of Pfizer from $36.00 to $30.00 in a report on Thursday, April 17th. UBS Group raised their price target on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Finally, Redburn Atlantic dropped their price target on Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $28.12.
View Our Latest Research Report on PFE
Pfizer Price Performance
PFE stock opened at $24.25 on Friday. The company has a market cap of $137.84 billion, a price-to-earnings ratio of 12.90, a PEG ratio of 0.87 and a beta of 0.52. The company has a current ratio of 1.16, a quick ratio of 0.96 and a debt-to-equity ratio of 0.65. The firm has a 50 day moving average of $24.42 and a 200-day moving average of $24.52. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43.
Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer's revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.60 earnings per share. As a group, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.
Pfizer Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.1%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio is 91.49%.
About Pfizer
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Articles
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
